PHARMACOTHERAPY REVIEW CNS STIMULANTS for treatment of ...
PHARMACOTHERAPY REVIEW CNS STIMULANTS for treatment of ...
PHARMACOTHERAPY REVIEW CNS STIMULANTS for treatment of ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
1415161718192021222324252627The Post Coronary Artery Bypass Graft Trial Investigators. The effect <strong>of</strong> aggressive lowering <strong>of</strong>low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes insaphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-62.Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes <strong>of</strong>aggressive lowering <strong>of</strong> low-density lipoprotein cholesterol levels and low-dose anticoagulation inthe post coronary artery bypass graft trial. Circulation 2000;102:157-65.Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk <strong>of</strong>stroke, and total mortality. An overview <strong>of</strong> randomized trials. JAMA. 1997;278:313-21.LaRosa JC, He J, Vupputuri S. Effect <strong>of</strong> statins on risk <strong>of</strong> coronary disease. A meta-analysis <strong>of</strong>randomized controlled trails. JAMA. 1999;282:2340-6.Plehn JF, Davis BR, Sacks FM, et al. Reduction <strong>of</strong> stroke incidence after myocardial infarctionwith pravastatin. The cholesterol and recurrent events (CARE) study. Circulation 1999;99:216-23.Expert Panel on Detection, Evaluation, and Treatment <strong>of</strong> High Blood Cholesterol in Adults.Executive summary <strong>of</strong> the third report <strong>of</strong> the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation and Treatment <strong>of</strong> High Blood Cholesterol in Adults (adult<strong>treatment</strong> panel III). JAMA. 2001;285:2486-97.Austin MA, Hokanson JE, Edwards KL, et al. Hypertriglyceridemia as a cardiovascular riskfactor. Am J Cardiol. 1998;81(4A):7-12.Krauss RM. Triglycerides and atherogenic lipoproteins: rationale <strong>for</strong> lipid management. Am JMed. 1998;105:505-62.Pearson TA, Laurora I, Chu H, et al. The lipid <strong>treatment</strong> assessment project (L-TAP): amultisource survey to evaluate the percentage <strong>of</strong> dyslipidemic patients receiving lipid loweringtherapy and achieving low density lipoprotein goals. Arch Intern Med. 2000;160:459-67.Hoerger TJ, Bula MV, Bray JW, et al. Treatment patterns and distribution <strong>of</strong> low-densitylipoprotein cholesterol levels in <strong>treatment</strong> – eligible U.S. adults. Am J Cardiol. 1998;82:61-65.McKenney JM. New cholesterol guidelines, new <strong>treatment</strong> challenges. Pharmocotherapy.2002;228:853-863.Denke MA, Grundy SM. Efficacy <strong>of</strong> low-dose cholesterol loweoirng drug therapy in men withmoderate hypercholesterolemia. Arch Intern Med. 1995;155:393-99.Gardner SF, Schneider EF, Granberry MC, et al. Combination therapy with low-dose lovastatinand niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996;16:419-23.Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three drug therapy with niacin, lovastatinand colestipol to reduce LDL cholesterol < 100 mg/dL in patients with hyperlipidemia and CAD.Am J Cardiol. 1997;80:111-15.25
Change language